The impact of extramedullary disease at presentation on the outcome of myeloma

Leukemia and Lymphoma

Volumn 50, Issue 2, 2009, Pages 230-235

  Wu, Ping ^a   Davies, Faith E ^a   Boyd, Kevin ^a   Thomas, Karen ^a   Dines, Sharon ^a   Saso, Radovan M ^a   Potter, Mike N ^a   Ethell, Mark E ^a   Shaw, Bronwen E ^a   Morgan, Gareth J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Extramedullary disease; High dose treatment; Myeloma; Thalidomide

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; METHOTREXATE; PREDNISONE; THALIDOMIDE; VINBLASTINE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BONE CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; EXTRAMEDULLARY MYELOMA; FEMALE; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG CANCER; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYELOMA; OVERALL SURVIVAL; PLASMACYTOMA; PLEURA CANCER; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SUBCUTANEOUS TISSUE TUMOR; THORAX WALL CANCER; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; RISK FACTORS; SPINAL CORD DISEASES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 61349195971     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802657751     Document Type: Article

References (16)

1. Blade, J., Kyle, R. A. and Greipp, P. R. (1996) Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol, 93, pp. 345-351.
2. Damaj, G., Mohty, M., Vey, N., Dincan, E., Bouabdallah, R. Faucher, C. et al. (2004) Features of extramedullary and extraosseous multiple myeloma: A report of 19 patients from a single center. Eur J Haematol, 73, pp. 402-406.
3. Blade, J., Perales, M., Rosinol, L., Montserrat, T., Silvia, M. Jordi, E. et al. (2001) Thalidomide in multiple myeloma: Lack of response of soft-tissue plasmacytomas. Br J Haematol, 13, pp. 422-425.
4. Rosinol, L., Cibeira, M. T., Blade, J., Esteve, J., Aymerich, M. Rozman, M. et al. (2004) Extramedullary myeloma escapes the effect of thalidomide. Haematologica, 89, pp. 832-836.
5. Biagi, J. J., Mileshkin, L., Grigg, A. P., Westerman, D. W. and Prince, H. M. (2001) Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant, 42, pp. 683-687.
6. Gonzalez-Porras, J. R., Gonzalez, M., Garcia-Sanz, R. and San Miguel, J F (2002) Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas. Br J Haematol, 119, pp. 883-884.
7. Dytfeld, D., Matuszak, M., Lewandowski, K. and Komarnicki, M. (2008) Bortezomib in combination with thalidomide and dexamethasone - a successful treatment regimen in refractory extramedullary multiple myeloma. Ann Hematol, 87, pp. 253-254.
8. Ali, R., Ozkalemkas, F., Ozkan, A., Ozkocaman, V., Ozcelik, T. Ozan, U. et al. (2007) Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon. Leuk Res, 31, pp. 1153-1155.
9. Rosinol, L., Cibeira, M. T., Uriburu, C., Yantorno, S., Salamero, O. Blade, J. et al. (2006) Bortezomib: An effective agent in extramedullary disease in multiple myeloma. Eur J Haematol, 76, pp. 405-408.
10. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol, 121, pp. 749-757.
11. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B. Gahrton, G. et al. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol, 102, pp. 1115-1123.
12. Attal, M., Harousseau, J. L., Stoppa, A. M., Sotto, J. J., Fuzibet, J. G. Rossi, J. F. et al. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med, 335, pp. 91-97.
13. Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E. Hawkins, K. et al. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med, 348, pp. 1875-1883.
14. Cavo, M., Zamagni, E., Tosi, P., Cellini, C., Cangini, D. Tacchetti, P. et al. (2004) First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica, 89, pp. 826-831.
15. Morgan, G. J., Davies, F. E., Owen, R. G., Rawstron, A. C., Bell, S. E. Cocks, K. et al. (2007) Thalidomide combinations improve response rates; results from the MRC IX study. Blood (ASH Annual Meeting Abstracts), 110, p. 3593.
16. Wu, P., Davies, F. E., Horton, C., Jenner, M. W., Krishnan, B. Alvares, C. L. et al. (2006) The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide-vincristine-doxorubicin-methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: A case-matched analysis. Leuk Lymphoma, 47, pp. 2335-2338.